Big Pharma Has More Going for It Than Obesity Drugs

After months of threats, President Trump eased up pressure on drugmakers late last year. That’s all it took for investors to notice that the beaten-down sector was actually growing just fine.

Talk of tariffs and aggressive drug-pricing regulation faded, giving way to headline-grabbing price deals between the White House and drugmakers that lifted two of the biggest policy overhangs on pharmaceutical stocks.